Varizig is intended for post-exposure prophylaxis of the Varicella Zoster Virus (VZV), meaning it is commonly used to provide supportive relief to individuals who have been exposed. Varizig is applied across therapeutic domains where short-term symptom management is appropriate following an exposure event.

This application is considered relevant for managing VZV exposure, especially in highly vulnerable populations, and may be part of symptomatic management in situations where VZV progression is a concern. The use of Varizig is generally relevant for easing the potential for severe VZV infection and may assist with managing the risk of serious complications.

Quick Fact: Relevant for Managing Post-Exposure Risk

Indications are commonly focused on specific high-risk groups, including non-immune pregnant women, severely immunocompromised individuals, and certain categories of exposed neonates and premature infants. This application contributes to easing the overall symptom load for these patients, whose conditions are marked by increased physiological stress.

“The application supports patients during difficult episodes by easing distress in situations where patients experience heightened symptoms.”

Regulatory References

1. DailyMed NLM label for VARIZIG

Eligibility Map: Who Can and Cannot Use Varizig

Official regulatory documents define Varizig eligibility based on risk and immune status, strictly limiting its use to high-risk individuals who lack evidence of immunity to the Varicella Zoster Virus (VZV).

Eligibility Scope
Populations for whom use is allowed: Immunocompromised children and adults, pregnant women, newborns of mothers with varicella shortly before or after delivery, premature infants, and infants less than one year of age.
Populations for whom use is contraindicated: Individuals with a history of anaphylactic or severe systemic reactions to human immune globulin preparations. This also includes IgA-deficient patients with antibodies against IgA due to the risk of anaphylactoid reaction.
Age-related eligibility rules: Use is established in high-risk pediatric subgroups, including neonates. Insufficient data exists for geriatric subjects (aged 65 and over) to determine differential response, and caution is advised due to their thrombotic risk.
Pregnancy and lactation eligibility status: Pregnant women are a specified high-risk population, but the label states: "Use only if clearly needed." Caution should be exercised when administered to a nursing mother.
Eligibility-related restrictions: The product must be administered via Intramuscular (IM) injection only; Intravenous (IV) administration is prohibited. Use in patients with a coagulation disorder is conditional and only permitted if the benefit outweighs the risks of IM injection.

---

Connection to the overall eligibility profile

Regulatory documents define eligibility through strict criteria that narrow its use primarily to non-immune, high-risk populations exposed to VZV. The profile establishes absolute prohibitions based on pre-existing hypersensitivity to immune globulins and prohibits IV administration. Other statements impose limitations or require caution based on the patient's age or underlying circulatory health.

Interactions with other medicines and products

The interaction profile of Varizig (Varicella Immunoglobulin, Human) is defined primarily by its function as a hyperimmune globulin, which affects the intended action of certain vaccines and other biological products. No documented interactions exist for metabolic enzymes, such as the CYP450 system, or transport proteins.

Documented Pharmacodynamic Interactions

The most significant interaction is the pharmacodynamic interference between Varizig and live attenuated virus vaccines (e.g., Measles, Mumps, Rubella, Varicella). The antibodies supplied by the immune globulin may impair the efficacy or interfere with the immune response generated by these vaccines.

This interaction requires a timing-based restriction where the administration of live attenuated virus vaccines must be deferred until approximately three months following Varizig administration. For the measles vaccine specifically, official documents suggest this necessary deferral period may be extended up to five months to minimize interference.

Exposure-Modifying Interactions

Co-administration with other medicines that bind to the human neonatal Fc receptor (FcRn), such as Efgartigimod alfa or Nipocalimab, may affect the concentration of the immune globulin. This is because these agents can compete for receptor binding, which may decrease the level or effect of the Varicella Zoster Immune Globulin.

How Varizig Works (Mechanism of Action)

Varizig operates by introducing pre-formed, specific antibodies (immunoglobulins) that function as the primary biological effector. This mechanism establishes passive immunization, wherein the antibodies directly bind to the Varicella-Zoster Virus (VZV) surface proteins, initiating the viral neutralization cascade. This specific binding establishes a mechanism that restricts the propagation of the virus within the humoral immune pathway.

The binding of these antibodies to the VZV structurally prevents the virus from attaching to host cell receptor sites, constituting a physical entry blockade mechanism. By modifying this early molecular step, Varizig interferes with the viral replication pathway before the transcription stage, which establishes a mechanism for the rapid, short-term interference with the initial stages of the replication pathway.

Through the formation of antibody-virus complexes, Varizig engages Fc-receptor pathways on immune cells, initiating a mechanism of accelerated pathogen clearance. This activity results in a mechanism that adjusts the activity of overactive or dysregulated viral propagation and influences regulatory feedback mechanisms within targeted immune pathways.

How to Use Varizig

Varizig (Varicella Zoster Immune Globulin, Human) is intended for a single, time-critical administration. The medicine is administered exclusively via intramuscular (IM) injection and is not for intravenous use. The dose is calculated based on the patient’s body weight in kilograms, with a maximum dose of 625 International Units (IU) for patients weighing 40.1 kg or more.

---

Dosing and Timing

Administration occurs as soon as possible following exposure to the Varicella Zoster Virus (VZV). While the optimal timing is within 96 hours (4 days) post-exposure, administration may be performed up to 10 days from the exposure event.

---

Administration Requirements

Varizig is supplied as a sterile solution in a single-use vial, requiring the solution to reach room temperature and be visually inspected for any particles before use. The calculated total dose is often divided and administered across multiple injection sites—such as the deltoid muscle or anterolateral thigh—to ensure no more than 3 mL is injected into any single location. The gluteal region is generally not used for routine administration. For patients who are at high risk and experience a second VZV exposure more than three weeks after the initial dose, a second full dose may be used.

Varizig: Recent Clinical Evidence

Clinical research on Varizig (Varicella Zoster Immune Globulin [Human]) primarily focuses on its use for post-exposure prophylaxis in high-risk, susceptible individuals. These individuals face an elevated risk of severe complications, such as pneumonia or encephalitis, if they contract varicella (chickenpox) after exposure to the Varicella Zoster Virus (VZV).

---

Efficacy and Outcomes

Studies have assessed the outcomes following Varizig administration in various high-risk groups, including immunocompromised patients, pregnant women, and infants.

• Disease Severity: A key finding across multiple trials and expanded-access programs indicates that Varizig administration is associated with a reduction in the severity of varicella infection, including lower incidence of complications and fewer severe cases (e.g., cases with greater than 100 lesions) when compared to historical data of untreated controls.
• Incidence: While Varizig is intended to reduce disease severity, its effect on completely preventing the onset of varicella infection is less definitive, with studies reporting varying rates of varicella development across different high-risk populations after receiving the product.
• Timing: Research supports administering Varizig as soon as possible after VZV exposure, ideally within 96 hours. However, data from expanded-access programs have also explored administration up to 10 days post-exposure, suggesting that this extended window may still offer attenuation (reduction in severity) of the resulting infection.

Safety and Tolerability

In clinical trials involving various high-risk patients, Varizig demonstrated an established safety profile. The most frequently reported adverse events were generally mild and included local reactions such as injection site pain and systemic symptoms like headache and nausea. Rare instances of severe adverse events, such as serum sickness, have been documented, consistent with other human immune globulin products.

Common questions about Varizig (FAQ)

Q: What is Varizig?

A: Varizig (Varicella Zoster Immune Globulin [Human]) is a solution of immunoglobulin G (IgG) antibodies prepared from the plasma of healthy donors who have a high level of antibodies against the varicella zoster virus (VZV), which causes chickenpox and shingles.

It is used to provide passive immunity—meaning immediate, temporary protection—to certain individuals at high risk for severe complications if they develop chickenpox.

Q: How is Varizig given?

A: Varizig is administered as a one-time injection directly into a muscle (intramuscularly, IM) or as an infusion into a vein (intravenously, IV). The route of administration depends on the product formulation and the patient's specific circumstances. It should be given as soon as possible after exposure to the virus.

Q: Who is Varizig given to?

A: Varizig is given to individuals at high risk for severe chickenpox complications who have had a significant recent exposure to VZV and are considered non-immune (meaning they have not been vaccinated and have not had chickenpox before). This typically includes:

• Immunocompromised patients (e.g., those with immune disorders or on immunosuppressive therapy)
• Newborn infants whose mothers developed chickenpox around the time of delivery
• Premature infants
• Pregnant women

The goal is to prevent or reduce the severity of the illness.

Q: Is Varizig a vaccine?

A: No, Varizig is not a vaccine. Vaccines stimulate your body to produce its own long-lasting antibodies (this is called active immunity).

Varizig is an antibody product that gives you ready-made antibodies from a donor, providing immediate, temporary protection (called passive immunity). The protection from Varizig lasts only for the duration that the injected antibodies remain in your system, which is typically a few weeks to months.

Q: How soon after VZV exposure must Varizig be given?

A: Varizig is most effective when given as soon as possible after exposure to the varicella zoster virus (VZV). The treatment should ideally be given within 96 hours (4 days) of the exposure to maximize its protective effect. The prescribing healthcare provider will assess the exposure timeline and the patient's risk factors to determine if treatment is appropriate.

How to Store and Dispose of Varizig?

The official storage and disposal guidelines for Varizig (Varicella Immunoglobulin, Human) are defined by regulatory agencies to ensure the stability of this specialized biological product.

Official Storage Requirements

Condition	Requirement
Temperature Range	Store the unopened vial under refrigeration at 2 C to 8 C (36 F to 46 F).
Freezing	Do not freeze the product, as this will damage the solution.
Light Protection	Keep the vial in its outer carton to protect it from light until the time of use.

Handling and Disposal

Varizig is for single use only. Once the vial is opened, the solution must be used immediately, and any unused portion must be discarded. Prior to use, the solution should be allowed to reach room or body temperature. Disposal of expired or unused medicine, including the empty vial, must be performed in accordance with local requirements for medicinal waste.